NASDAQ
1.63USD
-0.12 (-6.86%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
2.4M
P/E
—
EPS
—
Beta
-1.27
52W range
1.43-524
Day range
1.58–1.75
Open
1.74
Prev close
1.75
Volume
77.9K
Avg volume
2M
Dividend
0.00
IPO
2022-11-15
https://www.globenewswire.com/news-release/2026/07/28/3334151/0/en/Clearmind-Medicine-Successfully-Completes-Part-A-of-its-FDA-Regulated-Phase-I-II-Trial.html · 7/28/2026+0.80
https://www.globenewswire.com/news-release/2026/07/17/3329038/0/en/Clearmind-Medicine-Commends-Federal-Momentum-in-Advancing-Psychedelic-Based-Therapies-for-Mental-Health-and-Addiction.html · 7/17/2026+0.80
https://www.globenewswire.com/news-release/2026/07/07/3323070/0/en/Clearmind-Reports-Successful-Formulation-Feasibility-Study-Supporting-Potential-New-Additional-Route-of-Administration-Development-for-MEAI.html · 7/7/2026+0.60
https://www.globenewswire.com/news-release/2026/06/16/3312463/0/en/Clearmind-Medicine-Completes-Dosing-for-Part-A-of-its-of-FDA-Regulated-Phase-I-II-Clinical-Trial.html · 6/16/2026+0.60
https://www.globenewswire.com/news-release/2026/06/05/3307314/0/en/Clearmind-Medicine-to-Feature-New-Insights-from-CMND-100-Psychedelic-Clinical-Trial-on-Inside-MEAI-Webinar.html · 6/5/2026+0.40
https://www.globenewswire.com/news-release/2026/05/12/3292863/0/en/Clearmind-Medicine-Reaches-Important-Clinical-Milestone-20-Participants-Now-Treated-in-Ongoing-Phase-I-IIa-Trial-of-CMND-100-for-Alcohol-Use-Disorder.html · 5/12/2026+0.80
https://www.globenewswire.com/news-release/2026/04/27/3281528/0/en/Clearmind-Medicine-Announces-Evaluation-of-its-Psychedelic-Based-Treatment-MEAI-for-Potential-FDA-Breakthrough-Therapy-Designation.html · 4/27/2026+0.80
https://www.globenewswire.com/news-release/2026/02/06/3233766/0/en/Polyrizon-Signs-an-Agreement-to-Develop-Intranasal-Proprietary-Non-Hallucinogenic-Neuroplastogen-Formulation.html · 2/6/2026+0.60
https://www.globenewswire.com/news-release/2026/02/06/3233765/0/en/Clearmind-Medicine-Enters-into-Development-Agreement-to-Advance-Intranasal-Formulation-for-its-Proprietary-Non-Hallucinogenic-Neuroplastogen-MEAI.html · 2/6/2026+0.60
https://www.globenewswire.com/news-release/2025/12/24/3210333/0/en/Clearmind-Medicine-Reflects-on-a-Transformative-2025-Key-Clinical-Advancements-Expanded-Global-Reach-and-Strengthened-Foundation-for-Future-Growth.html · 12/24/2025+1.00
https://www.globenewswire.com/news-release/2025/12/12/3204638/0/en/Clearmind-Medicine-s-MEAI-Spotlighted-in-Prestigious-Review-Leading-Experts-Affirm-Transformative-Potential-for-Alcohol-Use-Disorder-Treatment.html · 12/12/2025+0.80
https://www.globenewswire.com/news-release/2025/12/01/3197063/0/en/Clearmind-Medicine-Charges-Forward-in-Alcoholism-Treatment-Positive-Cohort-Data-Full-DSMB-Approval-and-New-Elite-Site-Joins-the-Clinical-Trial.html · 12/1/2025+1.00
Clearmind Medicine Inc. is a pre-clinical biopharmaceutical company dedicated to pioneering the development of novel psychedelic-based treatments. Their primary goal is to address a variety of mental health and addiction challenges that currently lack adequate solutions. The company's research targets conditions such as alcohol use disorder (including problematic binge drinking), various eating disorders (like binge eating), depression, and other compulsive or "binge" behaviors. Founded in 2017, the company initially operated under the name Cyntar Ventures Inc. before officially rebranding as Clearmind Medicine Inc. in March 2021. Its operations are headquartered in Vancouver, Canada.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
